Latest Development Pipeline News

Immutep Limited’s shares have resumed trading following the release of an interim futility analysis from its pivotal TACTI-004 Phase III trial of eftilagimod alfa.

Imugene Limited has launched a $20 million capital raising through a $12 million institutional placement and an $8 million Share Purchase Plan, alongside a convertible notes amendment to support its clinical development pipeline.

Island Pharmaceuticals has partnered with the Burnet Institute to explore new antiviral applications for its lead drugs, targeting measles, chikungunya, and Ross River virus. This collaboration leverages existing data and government funding to enhance the company’s clinical pipeline without major capital outlay.

Complii FinTech Solutions reported a $1.35 million loss for H1 FY26 alongside a 6% increase in annual recurring revenue, driven by strategic platform upgrades and expanding client engagement.

Mustera Property Group reported a 45% revenue increase to $7.28 million for the half-year ending December 2025, driven by strong sales at its Forbes Residences project. Despite this growth, the company posted a net loss of $724,430, narrowing its deficit from the previous year as it advances its key North Fremantle development.

Dexus has announced a 19.3 cents per security distribution for HY26, aligned with its updated payout policy, alongside robust financial results and a strategic 10% on-market buyback to address valuation gaps.

Polymetals Resources has reported its maiden revenue from the Endeavor Mine with first concentrate shipments, yet posted a substantial half-year loss of $34.5 million. Operational setbacks and exploration advances mark a pivotal phase for the company.

Desane Group Holdings reports a modest half-year profit with stable assets and gearing, completes a key property sale, and pushes forward with a major industrial development in Penrith.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Ingenia Communities reports a steady first half of FY26, maintaining full-year guidance at the top of its range, driven by accelerating development settlements and growth across rental and holiday segments.

Neurotech International has reported positive long-term safety results for its lead drug candidate NTI164, bolstering its path towards regulatory approval and chronic use in paediatric neurological disorders.

Horizon Gold has reported significant high-grade gold intercepts from recent drilling at its Kingfisher prospect within the Gum Creek Gold Project, revealing new down-plunge extensions and enhancing the project's resource outlook.